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ABSTRACT
Cyclic AMP (cAMP) is an important negative regulator of T cell activation, and an increased level of cAMP is
associated with T cell hyporesponsiveness in vitro. We sought to determine whether elevating intracellular
cAMP levels ex vivo in alloreactive T cells during primary mixed lymphocyte reactions (MLR) is sufficient to
induce alloantigen-specific tolerance and prevent graft-versus-host disease (GVHD). Primary MLRs were
treated with exogenous 8Br-cAMP and IBMX, a compound that increases intracellular cAMP levels by
inhibition of phosphodiesterases. T cell proliferation and IL-2 responsiveness in the treated primary MLR
cultures were greatly reduced, and viable T cells recovered on day 8 also had impaired responses to restimu-
lation with alloantigen compared to control-treated cells, but without an impairment to nonspecific mitogens.
Labeling experiments showed that cAMP/IBMX inhibited alloreactive T cell proliferation by limiting the
number of cell divisions, increasing susceptibility to apoptosis, and rendering nondeleted alloreactive T cells
hyporesponsive to alloantigen restimulation. cAMP/IBMX-treated CD4 T cells had a markedly reduced
capacity for GVHD lethality in major histocompatibility complex class II disparate recipients, but maintained
the capacity to mediate other CD4 T cell responses in vivo. Thus, our results provide the first preclinical
evidence of using cAMP-elevating pharmaceutical reagents to achieve long-term alloantigen-specific T cell
tolerance that is sufficient to prevent GVHD.
© 2007 American Society for Blood and Marrow Transplantation
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Cyclic AMP (cAMP) is a second messenger uti-
ized by cells to regulate a variety of cellular functions.
levation of cAMP levels can stimulate proliferation
f various cell types, including epithelial cells, hepa-
ocytes, keratinocytes, and pancreatic islet  cells [1].
n contrast, proliferation of ﬁbroblasts, smooth mus-
le, neuronal, and lymphoid cells are known to be
nhibited by cAMP [2,3]. In T lymphocytes, cAMP
erves as an important negative regulator; elevated
AMP levels are associated with inhibition of activa- m
30ion and differentiation induced by signaling through
he T cell receptor (TCR) [4,5]. In humans, cAMP
evels in T cells from HIV-infected patients and indi-
iduals with common variable immunodeﬁciency are
levated, which renders these T cells hyporesponsive
o mitogenic stimulation [6,7]. It has also been shown
hat anergic T cell clones have increased levels of
ntracellular cAMP associated with the elevation of
27kip1 levels and the inhibition of antigen-speciﬁc
roliferation and IL-2 production [8].
The inhibitory function of cAMP is mediated pri-
arily through cAMP-dependent protein kinase A
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cAMP Induces CD4 Alloantigen-Specific Tolerance 531ype I (PKAI) [9]. This isoenzyme has been shown to
olocalize with the TCR during activation [10], and
ay activate C-terminal Src kinase, leading to inhibi-
ion of Lck-mediated TCR  chain phosphorylation
11]. cAMP-dependent PKAI can also mediate its neg-
tive regulatory function via the formation of a com-
lex between the cAMP response element binding
rotein and the cAMP response element modulator,
hich serves as an inhibitor for IL-2 gene transcrip-
ion [12]. Elevated levels of cAMP have also been
mplicated in the inhibition of protein kinase C, which
ay lead to the dysfunction of Ras pathways that are
ritical for T cell activation and IL-2 production [13].
AMP can also interfere with cell cycle progression by
ncreasing p27kip1 activity and decreasing cyclin D and
yclin E expression, which eventually leads to deacti-
ation of cyclin-dependent kinase (cdk)-2 and cdk4
nd cell cycle arrest at the G1 phase [8,14].
Intracellular levels of cAMP are controlled by 2
ypes of enzymes: adenyl cyclases, which use adeno-
ine triphosphate as a substrate to synthesize cAMP,
nd the cAMP-speciﬁc phosphodiesterases (PDEs),
hich catalytically hydrolyze cAMP to biologically
nactive adenosine 5=-monophosphate [15,16]. Clini-
ally approved reagents are being used to regulate the
unctions of these enzymes in vivo, and therefore
asily alter intracellular cAMP levels. Current clinical
ses of PDE inhibitors include the treatment of
sthma and chronic obstructive pulmonary disease
17,18].
Given the inhibitory nature of cAMP in T cell
roliferation and differentiation, we sought to exam-
ne the feasibility of using these pharmacologic re-
gents to elevate intracellular cAMP in alloreactive T
ells during primary mixed lymphocyte reactions
MLRs) to induce alloantigen-speciﬁc T cell tolerance
or graft-versus-host disease (GVHD) prevention. In
hese studies, 8Br-cAMP, a cell-permeable cAMP an-
log, and isobutyl-methylxanthine (IBMX), a com-
ound that prevents the degradation of intracellular
AMP by inhibiting PDEs [19], were used to treat
rimary MLR cultures containing puriﬁed CD4 T
ells as responders and irradiated major histocompat-
bility complex (MHC) class II disparate splenocytes
s stimulators. Our data demonstrated that combined,
Br-cAMP and IBMX-treated alloreactive T cells
ere hyporesponsive to alloantigenic stimulator cells,
hich was associated with an impairment in cell cycle
rogression and increased susceptibility to apoptosis.
hen treated T cells obtained from primary MLR
ultures were provided CD3 and CD28 signals, they
ailed to activate the Ras pathway as measured by
hosphorylation of ERK1 and ERK2 MAP kinases
nd to produce cytokines including IL-2. In vivo,
Br-cAMP/IBMX-treated cells had a substantially re-
uced capacity to cause GVHD lethality when infused
nto MHC class II disparate recipients. However, areated cells retained the capacity to mediate other
D4 T cell responses similar to control cultured
ells. Taken together, our data are consistent with a
odel where 8Br-cAMP/IBMX treatment induces al-
oantigen-speciﬁc T cell hyporesponsiveness during a
rimary MLR, which has potential for clinical appli-
ation for prevention of GVHD and other T cell-
ediated immune disorders.
ATERIALS AND METHODS
ice
B6.C.H2bm12/KhEg (termed bm12) mice and B6
ag-1/ mice were purchased from The Jackson
aboratory (Bar Harbor, ME). C57BL/6 (B6,
D45.2) and B6.Ly5.2/Cr (CD45.1) mice were
urchased from the National Institutes of Health (Be-
hesda, MD). B6 OT-II TCR transgenic mice were
enerated as described [20] and provided by Dr. Marc
enkins (University of Minnesota, Minneapolis, MN)
ith permission from Dr. William Heath (The
alter and Eliza Hall Institute, Victoria, Australia).
BBM74 TCR (B6 anti-bm12) transgenic mice were
enerated as described [21]. All mice were housed in a
peciﬁc pathogen-free facility in microisolator cages
ccording to NIH guidelines. Mouse studies have
een reviewed and approved by the University of
innesota Institutional Animal Care and Use Com-
ittee.
n Vitro MLR Cultures
CD4 T cells were isolated from lymph node
reparations as described [22]. Purity of the prepara-
ion was routinely95% CD4 T cells as determined
y FACS. Responder CD4 T cells were mixed with
rradiated (30 Gy), T- and NK-cell depleted bm12
plenic stimulators, which were prepared as described
22]. Cells were cultured at 37°C and 10% CO2 for 8
ays at 0.5 106/mL in 24-well plates (Costar, Acton,
A) in DMEM (BioWhittaker, Walkersville, MD)
ontaining 10% FBS (Hyclone, Logan, UT), 50 mM
-ME (Sigma, St. Louis, MO), 10 mM HEPES buffer,
mM sodium pyruvate (Life Technologies, Grand
sland, NY), amino acid supplements (1.5 mM L-
lutamine, L-arginine L-asparagine), (Sigma), and an-
ibiotics (100 U/mL penicillin; 100 mg/mL strepto-
ycin) (Sigma). IBMX (BIOMOL Research Labs,
lymouth Meeting, PA) and 8Br-cAMP (8-bromoad-
nosine 3=5=-cyclic monophosphate) (Sigma) were dis-
olved in DMSO and added to cultures at ﬁnal con-
entrations of 25 M and 50 M, respectively. To
onitor primary responses, 96-well round-bottom
icrotiter plates (Costar) were set up to contain 105
esponders and stimulators per well. To monitor sec-
ndary responses, 5  104 washed, viable responders
nd 105 irradiated (30 Gy) bm12 stimulators were
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M. J. O’Shaughnessy et al.532lated in the presence or absence of IL-2 (100 U/mL)
Amgen, Thousand Oaks, CA). In some experiments,
nti-CD3 plus anti-CD28 mAb-coated microspheres
23] (Dr. Carl June, Philadelphia, PA) were used to
timulate recovered T cells. Microtiter wells were
ulsed with tritiated thymidine (1 Ci/well) (Amer-
ham Life Sciences, Buckinghamshire, United King-
om) on the indicated days for 16 to 18 hours prior to
arvesting and counted in the absence of scintillation
uid on a -plate reader (Packard Instrument Com-
any, Meriden, CT) and analyzed in triplicate.
ytokine Analysis
Mixed lymphocyte reaction supernatants were ob-
ained for cytokine analysis and analyzed using a mul-
iplex assay kit (R & D Systems, Minneapolis, MN)
nd a Luminex analyzer (Austin, TX) according to the
anufacturer’s speciﬁcations. Sensitivity of the assay
as 2-3 pg/mL.
FSE Staining
Freshly puriﬁed CD4 T cells were stained with 1
M carboxyﬂuorescein diacetate succinimidyl ester
CFSE) (Molecular Probes, Eugene, OR) at a concen-
ration of 2.5  106/mL in PBS at room temperature
or 2 minutes with shaking. Labeling was stopped by
ddition of FCS to a ﬁnal concentration of 10%,
ollowed by washing 2 with cold 2% FCS in PBS.
alculations for responder frequency and proliferative
apacity were done as described [24].
low Cytometry
CD4 T cells were identiﬁed with either PerCP-
r allophycocyanin-conjugated anti-CD4 (RM4-5)
Ab. CD25 expression was determined by staining
ith PE-conjugated anti-CD25 (PC61) mAb. In some
xperiments, nonalloreactive OT-II and alloreactive
BBM74 transgenic CD4 T cells were identiﬁed
ased on positive staining with PE-conjugated anti-
5 TCR mAb and anti-V8 TCR mAb, respec-
ively. All mAbs were from Pharmingen (San Diego,
A), and staining was done according to manufac-
urer’s protocol. Determination of cell viability was
erformed by labeling cells with FITC- or allophyco-
yanin-conjugated Annexin V (Pharmingen) and/or
ropidium iodide according to manufacturer’s proto-
ol. All ﬂow cytometric experiments were done using
FACSCalibur (Becton Dickinson, San Jose, CA).
ACS Separation
3BBM74 TCR Tg T cells were separated from
ongenic B6 CD4 T cells (CD45.1) from day 6
ultures by staining with PE-conjugated mAb for the
ongenic marker CD45.1 (Pharmingen), followed by
rounds of anti-PE microbeads (Miltenyi, Auburn,
A), and application to MACS cell separation col- hmns (Miltenyi Biotec). The purity of 3BBM74
CR Tg cells in the negative selection fraction was
92%.
ell Cycle Analysis
Freshly puriﬁed B6 CD4 T cells were stimulated
ith plate-bound anti-CD3 (1 g/mL) and soluble
nti-CD28 (5 g/mL) at 1 million cells/mL in 24-well
ulture plates. The cells were washed and stained with
ITC conjugated anti-CD4 mAb (Pharmingen),
ashed again, and permeabilized with 0.1% Triton
-100 for 5 minutes on ice. Propidium iodide (50
g/mL) was added to the tubes and the samples ana-
yzed on a FACSCalibur for DNA content.
n Vitro Activation of T Cells and Immunoblotting
T cells isolated from MLR cultures were resus-
ended at 107 cells/mL and incubated with anti-CD3ε
hybridoma 145-2C11, hamster IgG1, provided by
r. Jeffrey Bluestone, San Franscisco, CA) (1 g/mL)
nd anti-CD28 (hybridoma 37.51, hamster IgG1, pro-
ided by Dr. James Allison, Berkeley, CA) (5 g/mL)
t 4°C for 20 min, washed, and incubated with goat
ntihamster IgG (10 g/mL) at 37°C for indicated
imes, and cell lysates were prepared as described
25]. Equal amounts of protein were analyzed by
0% SDS-PAGE on microgels, transferred to nitro-
ellulose membranes, and immunoblotted with mAb
or pERK1/2 (Santa Cruz Biotechnology, Santa Cruz,
A). Blots were stripped and reblotted with mAb for
RK1/2 (Upstate Biotechnology, Lake Placid, NY).
mmunodetection was performed by incubation with
orseradish peroxidase-conjugated anti-Ig (1:5000)
Promega, Madison, WI) as indicated by the host
rigin of the primary antibody and detected by auto-
adiography.
easurement of GVHD Lethality and
n Vivo Responses
bm12 recipients were sublethally irradiated by
xposing mice to 6 Gy total body irradiation (TBI)
rom a 137Cesium source at a dose rate of 85 cGy/
in. Four to 6 hours later, 105 freshly isolated B6
D4 T cells or day 8 cultured cells were injected
nto the lateral tail vein. To measure contact hyper-
ensitivity, 106 freshly isolated B6 CD4 T cells or
ay 8 cultured cells were injected into B6.Rag-1/
ice. After 30 days, mice were sensitized with 0.15
L 3% 4-ethoxymethylene-2-phenyloxazolone (ox-
zolone) (Sigma) in ethanol:acetone (3:1) on shaved
horacic and abdominal skin and then rechallenged 6
ays later on the right ear with 0.025 mL 1% ox-
zolone in acetone:olive oil (4:1) to induce a contact
ypersensitivity (CH) response [26]. Seventy-two
ours after challenge, swelling in the right ear was
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cAMP Induces CD4 Alloantigen-Specific Tolerance 533easured with a digital microcaliper (Fowler, New-
on, MA).
tatistical Analysis
Survival data were analyzed by life-table methods,
nd actuarial survival rates are shown. Group compar-
sons were made by log-rank test statistics. For all
ther data, statistical signiﬁcance was determined us-
ng Student’s t-test and P  .05 was considered sig-
iﬁcant.
ESULTS
Br-cAMP and IBMX Treatment Inhibits T Cell
roliferation and IL-2 Responsiveness in Primary
LR Cultures
Because activation of the cAMP pathway has been
hown to be a negative regulator of T cell activation,
e sought to determine whether the activation of this
athway was sufﬁcient to downregulate T cell prolif-
ration in primary MLR cultures. Highly puriﬁed
D4 T cells were incubated for 8 days with irradi-
ted, T cell-depleted MHC class II disparate splenic
timulators in the presence of 8Br-cAMP, a cell per-
eable cAMP analog. At a concentration of 50 M
Br-cAMP, T cell proliferation was reduced by 50% at
ime of peak proliferation (day 7), compared to vehi-
le-treated control cultures (Figure 1A, P  .004).
lthough viable cells recovered on day 8 of 8Br-
AMP-versus vehicle-treated cultures showed a de-
ayed response to restimulation with alloantigen (peak
roliferation at day 5 for 8Br-cAMP-treated versus day
for control-treated), peak proliferation upon re-
timulation was comparable to control cultures (data
ot shown). Because 8Br-cAMP could be catabolized
y endogenous phosphodiesterases in treated cells
hereby leading to suboptimal T cell hyporesponsive-
ess, we also tested the effects of IBMX to inhibit
ndogenous PDE activity. IBMX independently re-
uced T cell proliferation in primary MLR cultures,
ut inhibition was reproducibly greater when it was
dded together with 8Br-cAMP. As shown in Figure
A, 50 M 8Br-cAMP and 25 M IBMX inhibited
roliferation in a primary MLR culture by 90%
ompared to vehicle-treated control cultures (mean
nhibition at day 5 in 5 separate experiments was 92 	
%, P  .0002).
Analysis of culture supernatants indicated that
AMP/IBMX-treated primary cultures had signiﬁ-
antly less IL-2 present than control culture superna-
ants (Figure 1B, P .05). To determine if suboptimal
L-2 production was responsible for the impaired pro-
iferation observed in cAMP/IBMX-treated primary
LR cultures, some cAMP/IBMX-treated cultures
ere supplemented with exogenous IL-2 (100 U/mL).
ddition of exogenous IL-2 only partially reversed the pAMP/IBMX inhibition of T cells (P  .02 versus
AMP/IBMX-treated), indicating that a defect in IL-2
igure 1. Inhibition of T cell proliferation and IL-2 production by
Br-cAMP and IBMX. (A) Primary MLR cultures consisted of B6
D4T cells and bm12 splenic stimulators in the presence or absence
f 8Br-cAMP (50M) and/or IBMX (25M). All P-values.05 versus
ehicle except cAMP-treated on days 3 and 9. (B) Primary MLR
upernatants were analyzed in triplicate for soluble IL-2 on days 3, 5,
nd 7 of the culture. Mean concentration	 1 SEM is shown. (C) Some
ultures were supplemented with 100 U/mL exogenous IL-2 at initi-
tion of culture. IL-2 increases proliferation of cAMP/IBMX-treated
LR cultures (P .02). For all data points versus vehicle, P .03. On
he y-axis are mean cpm 	 1 SEM. On the x-axis are days in primary
ulture. Shown is 1 of 5 representative experiments.roduction alone was not responsible for the observed
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M. J. O’Shaughnessy et al.534nhibited proliferation of the cAMP/IBMX-treated
ells (Figure 1C). Alternatively, the elevated intracel-
ular cAMP levels might have reduced the ability of T
ells to respond to IL-2. Consistent with the latter
xplanation, ﬂow cytometric analysis of day 8 MLR
ells showed that whereas at least 50% of control-
ultured cells expressed CD25, the 
 subunit of the
L-2 receptor, 20% of cAMP/IBMX-treated cells
xpressed CD25 in all experiments (see Figure 2D),
uggesting that the failure to upregulate CD25 may
igure 2. Secondary hyporesponsiveness of 8Br-cAMP/IBMX-trea
Br-cAMP/IBMX-treated MLR cultures were washed free of treatm
P  .05 for cAMP/IBMX-treated cultures versus control at d
onsupplemented secondary MLR cultures were determined. (C) E
100 U/mL) (P  .03 for cAMP/IBMX versus control at days 2 and
f some secondary MLR cultures. On the y-axis is percent of CD
AMP/IBMX-treated versus control at all time points). (E) MLR
Ab-coated beads (105 per well) to assess proliferative responses (P
-axis are mean cpm 	 1 SEM; on the x-axis is days of secondary cu
ne of 3 representative experiments is shown.ontribute, at least in part, to the mechanism of
AMP/IBMX induced hyporesponsiveness in the pri-
ary MLR.
econdary Alloresponses of
Br-cAMP/IBMX-Treated Cells Are
nhibited Due to Decreased IL-2 Production
To study secondary in vitro responses, vehicle or
AMP/IBMX-treated T cells were recovered on day 8
R cultures is speciﬁc to alloantigen. (A) Day 8 vehicle-treated or
nd restimulated with fresh bm12 splenic stimulators (105 per well)
nd 4). (B) IL-2 levels in cell-free supernatants collected from
ents were performed as in (A) with the addition of exogenous IL-2
) Surface expression of CD25 was measured on days 0, 2, 4, and 6
cells in the designated culture that express CD25 (P  .002 for
red cells were restimulated with anti-CD3 mAb and anti-CD28
for cAMP/IBMX-treated versus control on days 2 and 6). On the
(F) CD25 expression and (G) IL-2 production were also measured.ted ML
ents a
ays 2 a
xperim
6). (D
4 T
cultu
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cAMP Induces CD4 Alloantigen-Specific Tolerance 535f a primary MLR, thoroughly washed, and equal
umbers of viable T cells were plated and restimulated
ith bm12 splenic stimulators. Prior to washing and
eplating, the viability of recovered cells was 54 	
0% (range 34%-86%) for vehicle-treated cells and
2 	 16% (range  6%-48%) for cAMP/IBMX-
reated cells (P  .02 versus vehicle-treated) as deter-
ined by Annexin V/PI staining. As shown in Figure
A, vehicle-treated cells responded vigorously to re-
timulation with alloantigen, whereas peak responses
f cAMP/IBMX-treated cells were reduced by 80%-
0% (P  .05), despite the fact that equal numbers of
iable cells were plated in both secondary cultures.
nalysis of culture supernatants for the presence of
oluble cytokines indicated that IL-2 was produced by
AMP/IBMX-treated cells, but levels were reduced by
70% (Figure 2B). To determine if inhibited second-
ry MLR responses resulted from decreased IL-2 pro-
uction, we supplemented secondary cultures with
xogenous IL-2 (100 U/mL). cAMP/IBMX-tolerized
ells showed minimal response to IL-2 supplementa-
ion at an early time point (day 2) of secondary culture,
ut responded vigorously at later time points (days
-6) when the culture contained exogenous IL-2 (Fig-
re 2C). Increased proliferation in response to alloan-
igen in the presence of exogenous IL-2 corresponded
o the time when cAMP/IBMX-tolerized cells became
ctivated and upregulated CD25 expression from
aseline levels of input cells in primary MLR cul-
ure (range  10%-15%) to 60% by day 4 of
econdary MLR culture (Figure 2D). Together,
hese data indicate that cAMP/IBMX-treated T
ells initially are hyporesponsive to alloantigenic
estimulation, associated with low CD25 expression
nd IL-2 production at early time points of second-
ry MLR culture, in contrast to control-treated
ells, which had evidence of a primed response to
lloantigen restimulation.
To determine whether the T cells were globally
nhibited in their function, we chose anti-CD3 mAb
nti-CD28 mAb-coated microbeads to ensure a sufﬁ-
ient mitogenic stimulus to all T cells to determine
he response of the entire culture. These mAbs pro-
ided a potent stimulus for proliferation of both con-
rol cultured and cAMP/IBMX-cultured cells (Figure
E). Compared to control-treated cells, cAMP/
BMX-treated cells had evidence of a modestly lower
roliferation response on day 2 that was equivalent
y day 4 of stimulation and exceeded that of con-
rol-treated cells on day 6. In comparison to alloan-
igen stimulation, cAMP/IBMX-treated cells that re-
ponded to anti-CD3 anti-CD28 mAbs upregulated
D25 expression earlier (Figure 2F) and produced
igher levels of IL-2 (Figure 2G). Thus, cAMP/IBMX
reatment renders alloreactive T cells hyporesponsive
o restimulation with alloantigen, but the remaining T
ells still have the capacity to mount a proliferative cesponse when stimulated through the TCR in a non-
peciﬁc manner with anti-CD3 and anti-CD28 mAbs.
hese data indicate that cAMP/IBMX-treated CD4
cells are not permanently and globally disabled.
Br-cAMP/IBMX Treatment Limits Proliferative
apacity of Alloreactive T Cells
To better understand the mechanisms responsible
or alloantigen-speciﬁc T cell hyporesponsiveness in-
uced by 8Br-cAMP/IBMX, puriﬁed CD4 T cells
rom 3BBM74 TCR transgenic mice were used as a
ource of alloantigen-speciﬁc T cells. These trans-
enic T cells are speciﬁcally reactive to bm12 alloan-
igen, and are easily identiﬁed in ﬂow cytometric anal-
sis by their characteristic TCR. To directly assess
esponses of nonalloreactive T cells, we used puriﬁed
D4 T cells from OT-II TCR transgenic mice that
re speciﬁcally reactive to OVAp rather than to the
m12 stimulators. To monitor cell division of these
ransgenic clones, they were labeled with CFSE and
dded to a primary MLR so that they each represented
0% of the total CD4 sample. As shown in Figure 3,
T-II cells largely remain undivided in both the ve-
icle-treated and cAMP/IBMX-treated groups. In
ontrast, a signiﬁcant fraction of 3BBM74 T cells had
ndergone multiple cell divisions in both groups (Ta-
le 1 and Figure 3). Quantitative analysis indicated
hat by day 4 of culture an average of 8% of naïve
ehicle-treated OT-II T cells and 2% of naïve cAMP/
BMX-treated OT-II cells had undergone at least one
ell division (Table 1). In contrast, an average of 59%
nd 55% of naïve alloreactive 3BBM74 TCR trans-
enic T cells from vehicle-treated and cAMP/IBMX-
reated groups, respectively, responded to stimulation
y undergoing cell division. On average, each allo-
eactive cell that divided gave rise to 17.1 daughter
ells in the control group, but only 6.9 daughter cells
n the cAMP/IBMX-treated group. Thus, cAMP/
BMX treatment of MLR cultures controls alloreac-
ive cell proliferation, at least in part by limiting the
roliferative capacity of activated alloreactive T cells,
ut not by limiting the frequency of responding allo-
eactive cells.
ctivated Cells Are Sensitized to Apoptosis by
Br-cAMP/IBMX Treatment, But Surviving
ells Are Anergic
It was possible that increased sensitization of ac-
ivated cells to apoptosis might contribute to the lim-
ted net proliferation of alloreactive T cells, thereby
ccounting at least in part for the reduced number of
aughter cells in the treated versus control MLR cul-
ures. To determine whether cAMP/IBMX treatment
nduces apoptosis in proliferating T cells, we exam-
ned apoptosis as measured by Annexin V binding and
ell division as measured by CFSE dilution of CFSE-
l
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M. J. O’Shaughnessy et al.536abeled B6 CD4 T cells that were stimulated with
nti-CD3  anti-CD28 mAbs in the presence or ab-
ence of cAMP/IBMX treatment. As shown in Figure
A, 9% of total CD4 T cells in the vehicle-treated
ulture were apoptotic. In contrast, cAMP/IBMX
reatment resulted in Annexin V binding in 20% of
otal CD4 T cells. As the number of cell divisions
ncreased for both groups the fraction of apoptotic
ells also increased, but at each stage, a larger fraction
f cAMP/IBMX-treated cells were apoptotic (Figure
B). We conclude from this experiment that cAMP/
BMX treatment increases susceptibility to apoptosis
hat is especially prominent as activated T cells accu-
ulate division events.
To further assess whether sensitization to apopto-
is by cAMP/IBMX treatment was associated with
ntigen stimulation, we analyzed MLR cultured and
igure 3. 8Br-cAMP/IBMX limits cell division of alloreactive CD4
OT-II) CD4 T cells were labeled with CFSE and added to pri
ransgenic cells were identiﬁed by TCR V usage, and CFSE
Br-cAMP/IBMX-treated cultures (heavy line). Day 0 control is s
epresentative experiments is shown.
able 1. 8Br-cAMP/IBMX Limits Proliferative Capacity of
lloreactive T Cells
Frequency of
Proliferation
Proliferative
Capacity
OT-II 3BBM74 OT-II 3BBM74
ehicle 8% 59% 5.1 17.1
AMP  IBMX 2% 55% 3.0 6.9
FSE-labeled alloreactive (3BBM74 TCR Tg) and nonalloreactive
(OT-II Tg) CD4 T cells were cultured with B6 CD4 T cells
and bm12 splenic stimulators in the presence or absence of
cAMP/IBMX. On day 4, V8 (3BBM74) or V5 (OT-II)
CD4 T cells were analyzed for CFSE dilution by ﬂow
cytometry. Frequency of proliferation is the proportion of
input 3BBM74 or OT-II CD4 T cells that responded to
stimulation by dividing. Proliferative capacity is the mean
number of daughter cells generated per naïve 3BBM74 or
OT-II CD4 T cell that divided. Data is from 1 of 3 repre-vsentative experiments.FSE-labeled 3BBM74 TCR transgenic CD4 T
ells for Annexin V binding. As shown in Figure 4C,
nly 16% of control-cultured 3BBM74 alloantigen-
peciﬁc cells were antigen-responsive (CFSElo quad-
ants) and bound Annexin V by day 3. In contrast,
0% of 3BBM74 CD4 T cells in the cAMP/IBMX-
reated MLR were CFSElo and bound Annexin V,
hich represents almost one-half of total antigen-
esponders. Similar results were obtained when the
ulk population of nontransgenic B6 CD4 T cells
hat also contain alloreactive T cells were analyzed
14% for control and 24% for cAMP/IBMX). Thus,
AMP/IBMX inhibited the division of both alloreac-
ive polyclonal and alloantigen-speciﬁc TCR transgenic
D4 T cells and, in addition, increased apoptosis in
oth cell populations at all numbers of cell division,
imilar to data shown in Figure 4B. As a consequence
f increased apoptosis, overall cell viability was re-
uced in cAMP/IBMX cultures as discussed above.
his overall reduction in cell viability is likely ac-
ounted for by the presence of fewer viable alloreac-
ive T cells at the end of culture.
To assess the function of alloreactive T cells that
ere not deleted and did not undergo apoptosis after
he primary MLR tolerization period, we studied the
econdary response of puriﬁed alloreactive TCR
ransgenic cells. Puriﬁed 3BBM74 T cells, separated
rom polyclonal T cells using CD45 alleleic determi-
ants, were obtained from day 6 control or cAMP/
BMX-treated cultures and then restimulated with
ither bm12 splenic stimulators or anti-CD3  anti-
D28 coated microbeads. Figure 5A shows that the
esponse of equal numbers of viable cAMP/IBMX-
reated alloreactive transgenic cells is reduced by 50%
s. Alloreactive transgenic (3BBM74) and nonalloreactive transgenic
LR cultures of B6 CD4 T cells and bm12 splenic stimulators.
n was measured on day 4 in control cultures (light line) and
istogram. Gates for each cell division are as indicated. One of 3T cell
mary M
dilutio
haded hersus control at day 2 of restimulation, and by 75%
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cAMP Induces CD4 Alloantigen-Specific Tolerance 537t days 4 and 6 of restimulation (P  .005 at all time
oints). The peak response to stimulation with anti-
D3/anti-CD28 coated beads was comparable for
oth groups, although the peak response was delayed
igure 4. 8Br-cAMP/IBMX treatment increases apoptosis in acti-
ated CD4 T cells. (A) B6 CD4 T cells were labeled with CFSE
nd stimulated with anti-CD3  anti-CD28 coated microbeads in
he presence or absence of cAMP/IBMX. On day 3 of culture,
FSE dilution and Annexin V binding were assessed. Cells in the
FSEhi quadrants had not undergone cell division. (B) Annexin V
inding was determined for each discrete population of daughter
ells from 0-6 cell divisions. (C) B6 CD4 T cells were combined
ith alloreactive 3BBM74 TCR transgenic CD4 T cells, labeled
ith CFSE, and stimulated with irradiated T cell-depleted bm12
timulators in the presence or absence of cAMP/IBMX. On day 3 of
he culture, transgenic T cells were identiﬁed by ﬂow cytometry
ith CD4 and V8 mAbs, and analyzed for CFSE dilution and
nnexin V staining. One of 3 representative experiments is shown.or cAMP/IBMX-treated alloreactive cells (Figure 5B). aecause puriﬁed cAMP/IBMX-treated alloreactive T
ells are hyporesponsive to restimulation with alloanti-
ens but not to stimulation via CD3 and CD28 signals,
e conclude that alloantigen—but not global—T cell
yporesponsiveness is induced by cAMP/IBMX treat-
ent in alloreactive T cells that survive the toleriza-
ion procedure.
Br-cAMP/IBMX Treatment of Stimulated T Cells
nhibits Cell Cycle Progression
To further probe the nature of the defect in pro-
iferative capacity of antigen stimulated cAMP/IBMX-
reated cells, we performed a basic cell cycle analysis
ased on propidium iodide staining of cellular DNA
ontent. Because a primary MLR culture cannot
rovide synchronized antigenic stimulation (data not
hown), we used anti-CD3  anti-CD28 stimulation
s a model of T cell activation for this analysis. Two
igure 5. Alloreactive T cells puriﬁed from 8Br-cAMP/IBMX-
reated MLR are hyporesponsive to alloantigen. 3BBM74 TCR Tg
cells (CD45.2) were cultured with congenic (CD45.1) wild-type
D4 T cells in control and 8Br-cAMP/IBMX-treated MLRs
or 6 days, separated by MACS, and restimulated with (A) bm12
plenocytes or (B) anti-CD3/anti-CD28 mAb-coated beads (105
er well). Proliferation of 105 of control or 8Br-cAMP/IBMX-
reated 3BBM74 Tg T cells was measured on days 2, 4, and 6 of
he culture. P  .007 for cAMP/IBMX-treated versus control at
ll time points.
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M. J. O’Shaughnessy et al.538eplicate experiments are shown in Table 2. By day 3
f stimulation, 30%-46% of CD4 T cells in the
bsence of cAMP/IBMX treatment had more than
iploid DNA content (2 N), indicating that they
ere at the S-phase of the cell cycle. At the same time
oint, only 4%-14% of cAMP/IBMX-treated cells
ere in the S-phase, whereas 75%-89% remained in
he G0/G1 phase. At day 5, signiﬁcantly fewer cells
rom the cAMP/IBMX group were in the S-phase
ompared to control (3%-29% versus 46%-47%).
otably, by day 5, the percentage of apoptotic CD4
cells (less than diploid DNA content) in the cAMP/
BMX-treated group was 29%-31%, compared to
%-18% of control cultured CD4 T cells, whereas
he percentage of cells in G0/G1 was comparable for
oth groups. Taken together, these data indicate that
AMP/IBMX treatment can decrease the number of
-cells that respond to TCR stimulation by progressing
o the S-phase of the cell cycle, and instead, may result
n cell death.
able 2. 8Br-cAMP/IBMX Treatment of anti-CD3  anti-CD28
Ab Stimulated CD4 T Cells Results in Decreased Progression
hrough the Cell Cycle
Vehicle cAMP  IBMX
<2N 2N >2N <2N 2N >2N
xpt 1
Day 1 11 82 7 10 86 4
3 6 65 30 11 75 14
5 6 48 46 29 42 29
xpt 2
Day 1 1 95 4 2 94 4
3 7 47 46 7 89 4
5 18 35 47 31 66 3
6 CD4 T cells were stimulated by plate bound anti-CD3 mAb
(1 g/ml) and soluble anti-CD28 mAb (5 g/ml). At 24, 72, and
120 hours, cells were subjected to cell cycle analysis. Percentage
of apoptotic (2N), non-cycling (2N) or cycling (2N) cells
was determined for CD4 T cells stimulated in the presence of
vehicle or 8Br-cAMP/IBMX. Data from two experiments are
shown.
igure 6. Defective ERK activation in T cells recovered from 8B
n day 7 from B6 anti-bm12 primary MLR cultures with or witho
ith anti-CD3 and anti-CD28 antibodies followed by crosslinki
repared and analyzed by SDS-PAGE followed by immunoblot w
RK1/2 mAb.efective TCR  CD28-Mediated ERK1/2
ctivation in T Cells Treated with
Br-cAMP/IBMX
Previous studies have shown that an altered pat-
ern of proximal biochemical events is induced when
nergic T cells are activated via their TCR even in
he presence of signals delivered via the CD28
ostimulatory pathway [27], including impaired
ctivation of mitogen-activated protein kinase
MAPK)/extracellular-regulated kinase (ERK) com-
onents of the Ras pathway. Because 8Br-cAMP/
BMX treatment rendered alloreactive T cells inca-
able of proliferation during primary and secondary
LR, we examined the status of ERK activation in
ultured cells from a B6 anti-bm12 MLR after
rosslinking of TCR/CD3 and CD28 with the rel-
vant antibodies. As shown in Figure 6, activation of
RK1/2 was completely inhibited in T cells that
ere treated with 8Br-cAMP/IBMX during primary
ulture then restimulated for 1 or 5 minutes. Im-
airment of the MAPK/ERK pathway by cAMP/
BMX treatment may result in the observed defects
n IL-2 production and cell cycle progression as we
ave observed in other types of alloantigen-speciﬁc
olerance [8,28].
Br-cAMP/IBMX-Treated Cells Have Reduced
apacity to Mediate Lethal GVHD
To determine whether in vitro hyporesponsiveness
o alloantigen induced by 8Br-cAMP/IBMX treatment
ould be preserved in vivo, we used a murine model of
VHD induction where transfer of 105 naïve B6
D4 T cells uniformly results in GVHD lethality in
ublethally irradiated bm12 recipients [22]. The infu-
ion of 105 naïve B6 CD4T cells resulted in GVHD-
nduced bone marrow aplasia and lethality within 30
ays after transfer of cells in all control mice (n  12)
Figure 7A). Likewise, infusion of 105 B6 CD4 T
ells recovered from an 8-day control-cultured MLR
P/IBMX-treated primary MLR culture. T cells were recovered
P/IBMX treatment. Subsequently, cells were incubated in vitro
rabbit antihamster Ig for 0, 1, or 5 minutes. Cell lysates were
ti-phosphoERK1/2 mAb. Blots were stripped and reprobed withr-cAM
ut cAM
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cAMP Induces CD4 Alloantigen-Specific Tolerance 539esulted in uniform lethality of all recipients (n  15).
n contrast, administration of 105 B6 CD4 T cells
rom an 8 day 8Br-cAMP/IBMX-treated MLR re-
ulted in signiﬁcant (P  .001) long-term survival
60 days) in 19 of 23 recipients. Taken together,
hese results indicate that ex vivo treatment of allo-
eactive T cells with 8Br-cAMP/IBMX was sufﬁcient
o reduce alloreactive T cell responses and to signiﬁ-
antly reduce lethal GVHD in MHC Class II dispar-
igure 7. 8Br-cAMP/IBMX-treated MLR cells have a signiﬁcant
A) Sublethally irradiated bm12 mice received 105 naïve (n  12
ells (n  23). Nineteen of 23 mice that received 8Br-cAMP/IBMX
f GVHD (P  .001 versus controls). Survival is indicated on the
eceived no cells (n  5) or 106 day 8 vehicle-cultured (n  4)
ere sensitized with 3% oxazolone on thoracic and abdominal s
hickness of the pinna was measured immediately before and
xazolone challenge is shown. Also shown is ear swelling on wild
nd abdominal skin with oxazolone (n  3) prior to challenge
ransferred cells versus unprimed B6 mice or Rag/ mice (P  .
hat received cAMP/IBMX-treated cells versus primed B6 mice
59, respectively).te recipients. pH Response Is Mediated by Adoptively
ransferred 8Br-cAMP/IBMX-Treated Cells
Although cAMP/IBMX-treated cells cause signif-
cantly less GVHD than fresh or control-cultured
ells, the ability of cAMP/IBMX-treated cells to re-
pond to nonalloantigen stimulation in vivo would
rovide evidence that this tolerization strategy is not
lobally inhibitory to T cell responses but rather is
ion in GVHD lethality but retain CD4 T cell function in vivo.
vehicle-cultured (n  15), or day 8 8Br-cAMP/IBMX-cultured
red cells survived long-term (60 days) without clinical symptoms
; days posttransfer of cells is on the x-axis. (B) B6.Rag-1/ mice
8 8Br-cAMP/IBMX-cultured cells (n  6). After 30 days, mice
d challenged with 1% oxazolone 6 days later on the right ear.
rs postchallenge. Ear swelling (mean 	 SEM) resulting from
6 mice that were either unprimed (n  2) or primed on thoracic
right ear. Ear swelling was signiﬁcant for mice that received
ereas no signiﬁcant differences were measured for Rag/ mice
/ mice that received vehicle-treated cells (P  .57 and P reduct
), day 8
-cultu
y-axis
or day
kin, an
72 hou
-type B
on the
05), wh
or Ragreferential for alloreactive T cell responses in vivo.
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M. J. O’Shaughnessy et al.540hus, we transferred 106 day 8 vehicle-cultured MLR
ells, 106 day 8 cAMP/IBMX-cultured MLR cells, or
o cells to B6.Rag-1/ recipient mice so that the
nly responding T cell population was from the adop-
ive transfer. After a 30-day period to allow T cell
epopulation to occur, recipient mice were sensitized
o 3% oxazolone on thoracic and abdominal skin and
hen rechallenged 8 days later with 1% oxazolone on
he right ear to induce a CH response. Because T cell
ctivation and homing to the site of inﬂammation are
ecessary steps for a CH response, measurement of
ar swelling in the challenged ear provides evidence
hat the adoptively transferred T cells could respond
n vivo to a neo-antigen. The results of this experi-
ent, shown in Figure 7B, indicate that mice that
eceived either day 8 control-cultured MLR cells or
ay 8 cAMP/IBMX-cultured cells exhibited similar
mounts of ear swelling when rechallenged with ox-
zolone (P  .57). The amount of ear swelling is also
quivalent to sensitized wild-type B6 mice with an
ntact immune system (P  .59). Wild-type B6 mice
hat were not sensitized to oxazolone and B6.Rag-
/ mice that received no adoptively transferred T
ells but were sensitized with oxazolone exhibited
inimal ear swelling when challenged with oxazolone
P  .05 versus transferred groups). Together, these
ata indicate that the response that occurred in
6.Rag-1/ mice receiving adoptively transferred
AMP/IBMX-treated cells resulted from a functional
n vivo response to oxazolone challenge that resulted
n equivalent CD4 T cell responses as control-
reated cells in vivo. Thus, despite having signiﬁcantly
educed capacity to mediate GVHD lethality, cAMP/
BMX-treated cells have the ability to mount func-
ional immune responses in vivo, which indicates that
he ex vivo cAMP/IBMX tolerization procedure pref-
rentially inhibits alloreactive T cell responses in vivo.
ISCUSSION
Cyclic AMP is a known physiologic inhibitor of T
ell activation. Although elevation of intracellular
AMP has been shown to induce T cell hyporespon-
iveness in vitro [8,29], it has not been formally proved
hat this method could achieve immune tolerance that
s sufﬁcient for prevention and treatment of T cell-
ediated diseases such as autoimmune disorders, graft
ejection, and GVHD following bone marrow trans-
lantation. In this paper, we showed that increasing
he intracellular cAMP level in alloreactive T cells
sing 8Br-cAMP and IBMX during a primary MLR
ould induce alloantigen speciﬁc T cell hyporespon-
iveness that was sufﬁcient to signiﬁcantly reduce the
apacity of CD4 T cells to induce GVHD without
lobally impairing CD4 T cell responses to other
timuli (oxazolone) in vivo. These data provide strong
vidence that suggests that pharmacologic regulation hf intracellular cAMP levels in pathogenic T cells
ould be an appropriate therapeutic target for the
odulation of unwanted immune responses.
Although an elevated level of intracellular cAMP
s uniformly suppressive to a polyclonal T cell popu-
ation, our data indicate that hyporesponsiveness only
ccurs in T cells that are antigen stimulated at the
ime of pharmacologically induced elevations in intra-
ellular cAMP. We conclude this based on the results
f in vitro experiments that showed cAMP/IBMX-
reated cells recovered from a primary MLR were
yporesponsive to restimulation with alloantigen, but
apable of intact responses to nonspeciﬁc TCR stim-
lation. Responses to nonspeciﬁc TCR stimulation
ere intact at 4 but not 2 days after removal from
AMP/IBMX containing cultures. Thus, we favor the
xplanation that the hyporesponsiveness of the cAMP/
BMX-treated cells in secondary culture resulted from
ntigen-speciﬁc tolerance or deletion without a sub-
tantial induction of hyporesponsiveness in the re-
aining nontolerized T cells. The relatively higher
esponse of control cultured cells to alloantigen re-
riming and more modest increase in early responses
o anti-CD3  anti-CD28 mAbs may represent the
inetic differences that would be expected to be seen
etween cultures that contained a frequency of anti-
en-primed T cells in contrast to the cAMP/IBMX-
reated cells that were comprised primarily of nonal-
oreactive, and hence primarily naïve, T cells. The
ailure of IL-2 supplementation to restore the alloan-
igen responses of cAMP/IBMX in secondary MLR
ultures indicates that IL-2 production is not respon-
ible for this defective response. The correlation of
D25 antigen expression levels with the response ki-
etics of alloantigen as well as anti-CD3 mAb 
nti-CD28 mAb induced stimulation may reﬂect the
onversion of antigen nonprimed, “naïve” cAMP/
BMX-treated cells to antigen-primed, “stimulated”
D4 T cells. Therefore, the kinetics of cAMP/
BMX-treated cells and CD25 upregulation in sec-
ndary culture would lag behind control cells that
ave already been stimulated in primary culture.
As mentioned previously, at least 2 major mecha-
isms, anergy and deletion of alloreactive T cells, may
ccount for the slow response of cAMP/IBMX-treated
ultured cells to alloantigen restimulation in vitro and
n vivo [30]. To date, it has not been clear whether an
levated cAMP level in T cells during antigen-stimu-
ation could result in cell death. However, it is known
hat cAMP can mediate apoptosis in some tumor cells
31] macrophages and pro-B cells [32]. Our ﬁndings
ndicate that alloreactive T cells in cAMP/IBMX-
reated MLRs had increased apoptosis, particularly in
lloreactive cells that had undergone cell division.
hus, induction of apoptosis in alloreactive T cells
ikely contributes to the observed in vitro and in vivo
yporesponsiveness.
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cAMP Induces CD4 Alloantigen-Specific Tolerance 541Although apoptosis limits the frequency of surviv-
ng alloreactive T cells, a fraction of alloreactive cells
urvive the cAMP/IBMX treatment. Puriﬁcation of
urviving Tg alloreactive cells indicated that an aner-
ic phenotype was induced in these cells. It is known
hat failure of cell cycle progression from the G1 to
-phase during TCR stimulation can lead to T cell
nergy [33]. It was previously shown that an elevated
evel of cAMP can interfere with cell cycle progres-
ion, possibly via a cAMP mediated increase of p27kip1
xpression [8,34]. p27kip1 is a cdk inhibitor whose
unction is to regulate G1 to S-phase transition of the
ell cycle [35]. In our experiments, 8Br-cAMP/IBMX
reatment impaired cell cycle progression, resulting in
ecreased frequency of cells in the S-phase. Another
allmark for anergic T cells is that they are viable but
o not proliferate upon antigen stimulation or pro-
uce IL-2 [36]. In our experiments, we showed that T
ells recovered from a 8Br-cAMP/IBMX-treated pri-
ary MLR culture did not proliferate and produced
igniﬁcantly reduced IL-2 upon alloantigen restimu-
ation. Interestingly, this secondary alloantigen-spe-
iﬁc hyporesponsiveness was reversible in the pres-
nce of exogenous IL-2 at time periods of CD25
pregulation, indicating that defective IL-2 produc-
ion was present in 8Br-cAMP/IBMX-treated T cells,
nd might be responsible in part for their unrespon-
iveness to alloantigen restimulation. Alternatively,
he slower kinetics of CD25 upregulation in cAMP/
BMX-treated T cells was simply reﬂective of the
esting state of the nonalloreactive T cells that dom-
nated the cAMP/IBMX and not the control culture.
We have previously reported using the same cul-
ure system and anti-CD154 mAb to induce tolerance
nd inhibit GVHD capacity of adoptively transferred
cells in vivo, exogenous IL-2 rescued both the
rimary and secondary MLR cultures from T cell
yporesponsiveness, in contrast to cAMP/IBMX, in
hich only the secondary alloantigen responses could
e rescued [37,38]. Despite the restorative effects of
xogenous IL-2 at 50 IU/mL on in vitro proliferation
f alloreactive T cells exposed to anti-CD154 mAb in
rimary MLR cultures, GVHD was not able to be
eadily generated in vivo in sublethally irradiated
m12 mice given adoptively transferred CD4 T cells
btained from anti-CD154 mAb-treated MLR cul-
ures even when recipients were given high doses of
xogenous IL-2 for 2 weeks posttransfer [37]. With
espect to the IL-2 production defect in cAMP/
BMX-treated cells, elevated intracellular cAMP level
ould lead to IL-2 production failure in T cells via
everal biochemical pathways, including inhibition of
he PKC pathway, which eventually leads to dysfunc-
ion of MAPK/ERK pathways and failure of IL-2
roduction [13,34,39]. Whether any persistent signal-
ng pathway defects may be responsible for the IL-2
roduction defect in the 8Br-cAMP/IBMX-treated Tells even at a normalized intracellular cAMP level in
econdary cultures remains to be determined. Alter-
atively, cAMP/IBMX treatment may inhibit CD25
pregulation per se, and when 8Br-cAMP and IBMX
re no longer present (at the time of secondary stim-
lation) CD25 upregulation can occur, which allows
xogenous IL-2 to restore proliferation.
The ability to selectively eliminate alloreactive re-
ponses while preserving in vivo immune function of
onor T cells is an important discovery that could be
f signiﬁcant value in many clinical settings. This
eature is particularly suitable for ex vivo tolerance
pplications [30] because of the ability to regulate
ntigen access, and hence stimulation, in this setting.
or example, one could use the method to speciﬁcally
arget GVHD causing alloreactive T cells but not
otential viral-speciﬁc or tumor-speciﬁc T cells. In
ddition to GVHD prophylaxis, the targeted antigen
peciﬁcity provided by an ex vivo tolerance approach
ould be advantageous for delayed lymphocyte infu-
ion treatment of bone marrow transplant patients
ith relapsed leukemia or severe viral infections. Be-
ause antileukemia and antiviral responses often require
D8 T cell function, future studies will be required to
xplore the effect of cAMP elevation on CD8 T cell-
ediated alloresponses in vitro and in vivo.
In summary, we have shown that elevation of in-
racellular cAMP levels results in tolerance sufﬁcient
o markedly inhibit GVHD while maintaining nonal-
oreactive T cell functions in vivo. These studies make
igniﬁcant progress toward validation of the principal
f using cAMP-elevating agents for ex vivo tolerance
nduction and potential in vivo therapeutic use for
revention and therapy of T cell-mediated immune
isorders including GVHD.
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